The study took place as the more highly transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation.
Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis. A mid-stage trial of the vaccine in South Africa, where a potent variant of the virus is common, showed 60% effectiveness among people who did not have HIV. Novavax shares rose 20% in after hours trading following the report, which comes on the day the United States reported its first cases of the South African variant. Novavax said the UK trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for regulatory review in Britain, the European Union and other countries. Some 27% of people in the trial are over age 65. The study took place as the more highly transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation, the US company announced in a news release.
